China is a country with a high prevalence of hepatitis B, with a large number of patients and extensive experience in its treatment. There are well-established treatment protocols for hepatitis B. Currently, the primary clinical approaches focus on antiviral therapy, inhibiting viral replication, and liver protection. Under the guidance of doctors at reputable hospitals, treatments include interferons such as Pegasys, Sinogen, and Yinduosu, as well as nucleoside antiviral drugs like Lamivudine, Adefovir, and Entecavir for targeted therapy. Additionally, liver protection treatments are administered using medications such as Bifendate, Stronger Neo-Minophagen C, Glycyrrhizin, and Ademetionine to effectively manage hepatitis B. However, achieving a complete cure for hepatitis B remains challenging at present.